Novel Therapies in Cancer Treatment – Myths and Facts about Clinical Trials
Presented by Lee Rosen, MD
About the Lecture
Lee Rosen, MD, UCLA Health Sciences Clinical Professor of Medicine, oncologist and Director of the Drug Development Program will discuss clinical trials as an important option always to consider for cancer care. His talk will discuss how new drugs are developed, how clinical trials are conducted and when they can/should be used in different stages of cancer treatment. He will also review classes of drugs just entering the clinical arena for a wide variety of cancer types. UCLA’s extensive list of studies provides patients with new options for their treatment, whether they have received therapy before or whether the diagnosis is new.
About the Speaker
Lee Rosen, MD is a Health Sciences Clinical Professor in the Division of Hematology/Oncology and Director of UCLA Phase I Program. Dr. Rosen is a principal investigator for many clinical trials focusing on new cancer drug development (Phase I), particularly in the treatment of gastrointestinal malignancies. He founded the Cancer Therapy Development Program. Dr. Rosen has made significant contributions to translational research with angiogenesis inhibitors, signal transduction inhibitors and new drug combinations. His work with angiogenesis inhibitors goes back to 1996 and he has since treated hundreds of patients with more than a dozen drugs in this of class. In 2004, Dr. Rosen created Premiere Oncology to continue the research he began in 1996 as founder of the Developmental Therapeutics Program at UCLA. The program was created following completion of his fellowship and was designed to conduct early stage (Phase I and Phase II) clinical trials of novel therapeutics designed to effectively treat patients with advanced solid tumors. Dr. Rosen rapidly developed a reputation for excellence in the conduct of gastrointestinal malignancy research and early stage clinical trials for patients with solid tumors. He has led pivotal clinical trials of many products subsequently approved by the United States Food and Drug Administration (FDA) for the treatment of cancer. In 2011, Dr. Rosen rejoined UCLA and is continuing with his clinical trial program.